Incretin Receptors in Non-Neoplastic and Neoplastic Thyroid C Cells in Rodents and Humans: Relevance for Incretin-Based Diabetes Therapy
暂无分享,去创建一个
[1] M. Culler,et al. Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency. , 2010, Endocrinology.
[2] K. Almholt,et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. , 2010, Endocrinology.
[3] J. Holst,et al. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances , 2010, Current opinion in endocrinology, diabetes, and obesity.
[4] N. Irwin,et al. Therapeutic potential for GIP receptor agonists and antagonists. , 2009, Best practice & research. Clinical endocrinology & metabolism.
[5] B. Ahrén. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes , 2009, Nature Reviews Drug Discovery.
[6] J. Holst,et al. Incretin-based therapy of type 2 diabetes mellitus. , 2009, Current protein & peptide science.
[7] J. Holst,et al. The incretin system and its role in type 2 diabetes mellitus , 2009, Molecular and Cellular Endocrinology.
[8] C. Mcintosh,et al. Glucose-Dependent Insulinotropic Polypeptide-Mediated Up-Regulation of β-Cell Antiapoptotic Bcl-2 Gene Expression Is Coordinated by Cyclic AMP (cAMP) Response Element Binding Protein (CREB) and cAMP-Responsive CREB Coactivator 2 , 2007, Molecular and Cellular Biology.
[9] J. Holst. The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.
[10] J. Reubi,et al. GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting , 2007, Journal of Nuclear Medicine.
[11] H. Höfler,et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans , 2006, Proceedings of the National Academy of Sciences.
[12] D. Drucker,et al. Glucagon and glucagon-like peptide receptors as drug targets. , 2006, Current pharmaceutical design.
[13] R. Pederson,et al. Glucose-Dependent Insulinotropic Polypeptide Promotes β-(INS-1) Cell Survival via Cyclic Adenosine Monophosphate-Mediated Caspase-3 Inhibition and Regulation of p38 Mitogen-Activated Protein Kinase , 2003 .
[14] J C Reubi,et al. Unexpected high incidence of cholecystokinin‐B/gastrin receptors in human medullary thyroid carcinomas , 1996, International journal of cancer.
[15] C. Massart,et al. Effect of S9788 on the efficiency of doxorubicin in vivo and in vitro in medullary thyroid carcinoma xenograft , 1996, Anti-cancer drugs.
[16] M. Santoro,et al. Point Mutation of the RetProto-oncogene in the TT Human Medullary Thyroid Carcinoma Cell Line , 1995 .
[17] M. Santoro,et al. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. , 1995, Biochemical and biophysical research communications.
[18] J. Reubi,et al. Evaluation of somatostatin biosynthesis, somatostatin receptors and tumor growth in murine medullary thyroid carcinoma. , 1994, European journal of endocrinology.
[19] B. Thorens. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[20] B. Franc,et al. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[21] G. Boorman,et al. Naturally occurring medullary thyroid carcinoma in the rat. , 1972, Archives of pathology.